Regulatoriskt pressmeddelande

Cereno Scientific publishes Annual Report for 2025

Cereno Scientific (Nasdaq First North: CRNO B), a biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today published its Annual Report 2025, highlighting clinical program progress and the opportunities ahead. An update is provided on the financial runway assumptions.

The Annual Report is now available digitally in English and Swedish at https://www.cerenoscientific.com/en/investors/financial-reports.

2025 marked a pivotal year for Cereno Scientific
Building on encouraging Phase IIa data with our leading, the Company’s lead HDAC inhibitor program, CS1, advanced into a regulatory-aligned and operationally ready global Phase IIb trial. In parallel, our second HDAC inhibitor candidate, CS014, delivered positive Phase I results and progressed toward Phase II, reinforcing the depth and scalability of our epigenetic HDAC inhibitor platform.

2026 outlook: near-term value-driving milestones across the pipeline

CS1 – further analyses of data from the EAP in Q2
CS1 – the first patient in the Phase IIb trial in June
CS014 – PK bridging study to be completed in mid-year
CS014 – IND submission and approval in H2
CS585 – initiating preclinical studies in APS disease models in H1

Update on the financial runway assumptions
In accordance with applicable accounting standards and established market practice, the Board of Directors has assessed the Company's ability to continue as a going concern. The Annual Report has accordingly been prepared on a going concern basis. Further formal statements may be found within the Annual Report in the Administration Report and Auditor’s Report.

Chair of the Board Jeppe Øvlesen, comments: “Our scientific and commercial potential has significantly increased. We are confident in our ability to secure capital as needed to support the company’s continued growth towards upcoming value-driving milestones.”

About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. The company’s innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12-months treatment. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed favorable safety and tolerability profile in Phase I, development focus for Phase II is pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.